Methodological Quality of Pulmonary Arterial Hypertension Treatment Evidence-Based Guidelines: A Systematic Review Using the AGREE II and AGREE REX Tools
Cardiovascular Drugs and Therapy · 2025-12 · 39 (6) · 1353-1363
DOI: 10.1007/s10557-024-07605-w ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 09.07.2024. Verfasst von Ana Paula Oliveira Vilela und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Assistance Postgraduate Program, Federal University of Paraná, Curitiba, Brazil. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Practice Guidelines as Topic, Evidence-Based Medicine, Antihypertensive Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Instituto Politécnico de Lisboa.
Abstract (Originalsprache)
Purpose
Pulmonary arterial hypertension (PAH) is a progressive disease with a poor prognosis, and its management should be grounded in well-developed clinical practice guidelines (CPG). Thus, we critically assess the methodological quality of the available CPG for pharmacological treatments for PAH.
Methods
A systematic review (CRD42023387168) was performed in PubMed, Cochrane, Embase, and Tripdatabase (Jan-2023). Eligible records were appraised by four reviewers using the Appraisal of Guidelines, Research, and Evaluation Collaboration tool (AGREE II) and the complementary tool for assessing recommendations’ quality and certainty, AGREE REX. Descriptive statistics were used to summarize the data.
Results
Overall, 31 guidelines, mainly authored by professional societies (90%), targeting only physicians as primary users (84%), were identified. Guidelines presented a moderate overall quality (scores of 63% and 51% in AGREE II and AGREE REX, respectively), with a few domains showing slight improvements over the years. AGREE II “Scope and Purpose” (94%) and “Presentation Clarity” (99%) domains obtained the highest scores. The items related to “Stakeholder involvement,” “Editorial independence,” and “Clinical applicability” (AGREE REX) were fairly reported. Conversely, CPG lacks rigor in development (32% score, AGREE II), scarcely discusses the role of stakeholders, and provides deficient data on the implementation of recommendations (scores of 35% and 46% in AGREE II and AGREE REX, respectively). No differences in the quality of guidelines published by different developers or countries were observed ( p > 0.05).
Conclusion
Methodological weaknesses are common among guidelines addressing PAH treatment, especially regarding scientific rigor, stakeholders’ values and preferences, and facilitators and barriers to implementability. Particular attention should be given to developing future guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Assistance Postgraduate Program, Federal University of Paraná, Curitiba, Brazil.
- Pharmaceutical Sciences Postgraduate Program, Universidade Federal Do Paraná, Curitiba, Brazil.
- Health Technology Assessment Unit, Oswaldo Cruz German Hospital, São Paulo, Brazil.
- Pharmaceutical Sciences Postgraduate Program, Federal University of Paraná, Curitiba, Brazil.
- Pharmaceutical Sciences Postgraduate Program, Federal University of Paraná, Curitiba, Brazil. fernanda.tonin@estesl.ipl.pt.
- H&TRC-Health & Technology Research Center, ESTeSL-Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Av. Dom João II Lote 4.69 01, 1990-096, Lisbon, Portugal. fernanda.tonin@estesl.ipl.pt.
ORCID-Profile: Ana Paula Oliveira Vilela, Flávia Deffert, Rosa Camila Lucchetta, Yara Maria da Silva Pires, Felipe Fernando Mainka, Fernanda S Tonin, Roberto Pontarolo
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Instituto Politécnico de Lisboa
Zitieren
APA
Vilela, A. P. O., Deffert, F., Lucchetta, R. C., da Silva Pires, Y. M., Mainka, F. F., Tonin, F. S., & Pontarolo, R. (2025). Methodological Quality of Pulmonary Arterial Hypertension Treatment Evidence-Based Guidelines: A Systematic Review Using the AGREE II and AGREE REX Tools. Cardiovascular Drugs and Therapy, 39(6), 1353-1363. https://doi.org/10.1007/s10557-024-07605-w
Vancouver
Vilela APO, Deffert F, Lucchetta RC, da Silva Pires YM, Mainka FF, Tonin FS, et al. Methodological Quality of Pulmonary Arterial Hypertension Treatment Evidence-Based Guidelines: A Systematic Review Using the AGREE II and AGREE REX Tools. Cardiovascular Drugs and Therapy. 2025;39(6):1353-1363. doi:10.1007/s10557-024-07605-w
BibTeX
@article{Vilela2025,
author = {Vilela, Ana Paula Oliveira and Deffert, Flávia and Lucchetta, Rosa Camila and da Silva Pires, Yara Maria and Mainka, Felipe Fernando and Tonin, Fernanda S and Pontarolo, Roberto},
title = {Methodological Quality of Pulmonary Arterial Hypertension Treatment Evidence-Based Guidelines: A Systematic Review Using the AGREE II and AGREE REX Tools},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
volume = {39},
number = {6},
pages = {1353--1363},
doi = {10.1007/s10557-024-07605-w}
}
EUVIMED